

## To determine the prevalence of primary and secondary infections among the clinically suspected cases of dengue

Ritu<sup>1</sup>, Shiv Shankar Prasad<sup>2\*</sup>, Hira Lal Mahto<sup>3</sup>

<sup>1</sup>Tutor, Department of Microbiology, Nalanda Medical College and Hospital, Patna, Bihar, India

<sup>2</sup>Assistant Professor, Department of Geriatric, PMCH, Patna, Bihar, India

<sup>3</sup>Professor and HOD, Department of Microbiology, Nalanda Medical College and Hospital, Patna, Bihar, India

Received: 07-10-2020 / Revised: 30-12-2020 / Accepted: 07-01-2021

### Abstract

**Background:** Dengue is currently regarded globally as the most important mosquito borne viral diseases presenting with varied symptomatology. Epidemiology and clinical presentation of dengue infection differs significantly across geographical areas in India. **Aim:** To determine the prevalence of primary and secondary infections among the clinically suspected cases of dengue. **Material and methods:** This was a prospective observational study conducted in the Department of Microbiology Nalanda Medical College and Hospital, Patna, Bihar, India from Oct 2019 to may 2020. A total of 600 serum samples from suspected dengue cases attending OPD or admitted in the hospital were tested for the confirmation of Dengue. We have received blood samples in our microbiology laboratory, the blood samples were allowed to clot at room temperature and then we centrifuged the samples and serum samples were separated. From the serum samples we have done NS1 Ag and IgM Ab testing by ELISA. **Results:** Out Of 600, 120 samples were positive for dengue. Seroprevalence of Dengue was 20%.80 (66.67 %) were male patients and 40 (33.33 %) were female patients. 88(73.33%) patients were from urban area and 32(26.67%) from rural area. The dengue infection was observed more (28.33%) in the age group 20 to 30 years followed by 10 to 20 years (25.83%) and 30 to 40 years (22.5%). All dengue positive patients in our study had fever of 2 to 7 days. The most common presenting symptoms of dengue were fever with body ache (45.83%), headache (37.5%), nausea 34.17%) and vomiting (24.17%) and fever with rash was observed in 9 cases(7.5%). Out of 120 dengue cases, NS1/NS1+IgM/IgM were positive for 103(85.83%) patients, suggesting primary infection. IgM and IgG positive was seen in 8(6.67%) patients, suggesting late primary or early secondary infection. IgG was positive in 9(7.5%) cases, suggesting secondary or past infection. Thrombocytopenia ( $<1,00,000/\text{mm}^3$ ) was observed in 45(37.5%) cases. In 7(5.83%) patients platelet count was  $< 20,000/\text{mm}^3$ . **Conclusion:** Effective implementation of vector control measures through efforts toward vector breeding source reduction help in reduction of the dengue prevalence in community. This prevention measures will be helpful to us for decreasing other vector borne diseases simultaneously.

**Keywords:** Dengue, NS1 antigen, IgM antibody, Seroprevalence.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

### Introduction

Dengue is one of the most serious mosquito borne viral infection of man affecting mainly tropical and subtropical countries caused by dengue viruses (DV) belonging to family Flaviviridae. There are four serotypes of the virus referred to as DV-1, DV-2, DV-3

and DV-4. It spreads through the bite of infected female Aedes mosquito[1]. All four serotypes of dengue virus can cause full spectrum of disease from a subclinical infection, the dengue fever (DF) and a severe disease that may be fatal, the dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS).[2] The Infection with any one serotype confers an individual life-long immunity to that same serotype but it has cross reactivity to the other serotype. Secondary infection with another serotype or multiple infections with different serotypes leads to severe form of dengue dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) due to this

\*Correspondence

**Dr Shiv shankar Prasad**

Assistant Professor, Department of Geriatric ,  
PMCH, Patna, Bihar, India.

**E-mail:** [drsspd123@gmail.com](mailto:drsspd123@gmail.com)

cross-reactivity[3].The incidence of dengue has increased over last 50 years with 2.5 billion people living in areas where dengue is endemic[4].It affects 100 million people each year with 500,000 cases of DHF and DSS with around 30,000 deaths mostly among children.<sup>1</sup> It is known that early and specific diagnosis of DHF and DSS followed by supportive therapy reduces mortality and morbidity.[5] Viral Isolation by cell culture and subsequent detection by immunofluorescence, though the gold standard tests for identification of dengue infection are not within the reach of peripheral and even most tertiary care laboratories.[6] For a long time, detection of dengue specific IgM/IgG has been the main stay of diagnosis of dengue infection. Antibody detection is an indirect method of diagnosis and therefore is prone to false positive as well as false negative results.[7] NS1 antigen is detectable from day 1 of fever both in primary and secondary infections. NS1 is shown to be highly specific viral marker making it extremely reliable parameter for diagnosis of dengue infection from day 1 of fever.[8]

A small percentage of persons who have previously been infected by one dengue serotype develop bleeding and endothelial leak upon infection with another dengue serotype. This syndrome is termed severe dengue (reclassified in 2009 by the WHO, previously referred to as dengue hemorrhagic fever and dengue shock syndrome). Severe dengue has also been termed dengue vasculopathy. Vascular leakage in these patients results in hemo concentration and serous effusions and can lead to circulatory collapse. This, in conjunction with severe hemorrhagic complications,

can lead to a shock syndrome, which poses a greater fatality risk than bleeding per se.[9] Dengue is endemic to the Indian sub-continent. Dengue is associated with explosive urban epidemics and has become a major public health problem in India.[10]

**Material and Methods**

This was a prospective observational study conducted in the Department of Microbiology Nalanda Medical College and Hospital, Patna, Bihar, India from oct 2019 to May 2020. after taking the approval of the protocol review committee and institutional ethics committee. A total of 600 serum samples from suspected dengue cases attending OPD or admitted in the hospital were tested for the confirmation of Dengue. All the age group patients were include in this study. A suspected case of dengue was considered a patient with signs and symptoms like headache, retro-orbital pain, myalgia, arthralgia, rash and haemorrhagic manifestation, etc. Serum samples from these patients were tested for Dengue NS1 antigen using dengue NS1 antigen capture ELISA (PanBio Diagnostics) and dengue IgM antibody by dengue IgM capture ELISA (PanBio Diagnostics) for the confirmation of dengue cases. ELISA tests were performed as per the manufacturer’s instructions. We have received blood samples in our microbiology laboratory, the blood samples were allowed to clot at room temperature and then we centrifuged the samples and serum samples were separated. From the serum samples we have done NS1 Ag and IgM Ab testing by ELISA.

**Results**

**Table 1: Seroprevalence of Dengue**

Total no of patients	Dengue positive patients	%
600	120	20

Out Of 600, 120 samples were positive for dengue. Seroprevalence of Dengue was 20%. Table 1

**Table 2: Demographic profile of patients**

Gender	N=120	%
Male	80	66.67%
Female	40	33.33%
<b>Age years</b>		
Below 10	12	10%
10-20	31	25.83%
20-30	34	28.33%
30-40	27	22.5%
40-50	10	8.33%
Above 50	6	5%
<b>Area</b>		
Urban	88	73.33%
Rural	32	26.67%

Out of 120 dengue patients 80 (66.67 %) were male patients and 40 (33.33 %) were female patients. Out of 120 dengue patients, 88(73.33%) patients were from urban area and 32(26.67%) from rural area. In our study dengue infection was observed more (28.33%) in the age group 20 to 30 years followed by 10 to 20 years (25.83%) and 30 to 40 years (22.5%).

**Table 3: Clinical profile of dengue patients**

Clinical presentation	No of Patients	%
Fever + myalgia	13	10.83%
Fever + rash	9	7.5%
Fever + headache	45	37.5%
Fever+ nausea	41	34.17%
Fever + vomiting	29	24.17%
Fever + arthralgia	20	16.67%
Fever + bodyache	55	45.83%
Fever + itching	15	12.5%

All dengue positive patients in our study had fever of 2 to 7 days. The most common presenting symptoms of dengue were fever with body ache (45.83%), headache (37.5%), nausea (34.17%) and vomiting (24.17%). Out of 120 dengue cases fever with rash was observed in 9 cases (7.5%). Table 3.

**Table 4: Serology results of rapid dengue tests**

Test results	No. of patients	%
NS1/NS1+IgM/IgM Positive	103	85.83%
IgG Positive	9	7.5%
IgG + IgM Positive	8	6.67%
Total	120	100%

Out of 120 dengue cases, NS1/NS1+IgM/IgM were positive for 103 (85.83%) patients, suggesting primary infection. IgM and IgG positive was seen in 8 (6.67%) patients, suggesting late primary or early secondary infection. IgG was positive in 9 (7.5%) cases, suggesting secondary or past infection. Out of all dengue cases thrombocytopenia ( $<1,00,000/\text{mm}^3$ ) was observed in 45 cases. In 7 patients platelet count was  $<20,000/\text{mm}^3$ .

### Discussion

Total 600 blood samples of the patients suspected of having dengue infection were tested in the laboratory by rapid immunochromatography tests for NS1 Ag, IgG and IgM. Out of these 120 samples were positive for dengue. Seroprevalence of Dengue was 20%. 11.92% prevalence was reported by P. Jyoti and B Metri [11]. 18.99% prevalence was observed over period of 2008 to 2011 by Sood S in Rajasthan [12]. Low prevalence 3.55% was reported by Kumar M et al. [13]. A study from central India reported 31.3% prevalence rate. [14]

Out of 120 dengue patients 80 (66.67 %) were male patients and 40 (33.33%) were female patients. Similar

result was observed by Kumar M et al, in their study out of total positive dengue cases, 62.63% were males and 37.37% females. [13] Many studies have observed higher prevalence of dengue infection among males than females. [11,12,15,16]

In our study, out of 120 dengue patients, 88 (73.33%) patients were from urban area and 32 (26.67%) were from rural area. Similar results were by Ahammad F Set al. (2016), 109 cases (75%) were from rural area where as 25 cases (25%) were from urban area. [16] According to their report the rural broadening of dengue infection is comparatively a recent phenomenon which is supposed to be linked with the shortage of water in rural areas, designing of schemes for water supply to the rural areas and development of newer water transport system in the rural places.

In our study most of the dengue patients were from age group 20 to 30 years (28.33%) followed by 10 to 20 years (25.83%) and 30 to 40 years (22.5%). Kumar M et al in their study observed maximum dengue cases in age group 10-20 years (31.58%) and 21 to 30 years (15.78%). [13] Kale et al, observed commonest age group affected was (34%) was between 11-15

years.[15] Some Indian studies have reported that dengue infection is more common in children.[17,18] All dengue positive patients in our study had fever of 2 to 7 days. The most common presenting symptoms of dengue were fever with body ache (45.83%), headache (37.5%), nausea 34.17% and vomiting (24.17%). Out of 120 dengue cases fever with rash was observed in 9 cases (7.5%). Similar clinical presentation was observed by Mahesh Kumar et al, fever was present in almost all cases (n=380) followed by, headache (n=274), joint pain (n=2432), myalgia (n=144), retro-orbital pain (n=141), backache (n=95), skin rash (n=80).[13]

Out of 120 dengue cases, NS1/NS1+IgM/IgM were positive for 103(58.83%) patients, suggesting primary infection. IgM and IgG positive was seen in 8(6.67%) patients, suggesting late primary or early secondary infection. IgG was positive in 9 (7.5%) cases, suggesting secondary or past infection. Mahesh Kumar et al reported that, Out of the 380 dengue positive cases, 136(35.79%) were NS-1 positive, 117(30.79%) were IgM positive, 38(10%) were IgG positive, 71(18.68%) were IgG/IgM positive, 14(3.68%) were IgG NS- 1/IgMNS-1 positive and 4(1.05%) were IgG/IgMNS-1 positive.[13]

Though among methods used for diagnosis of dengue the virus isolation, molecular methods are more specific tests, facilities are not available in all institutes. Serological tests are most commonly used in most of the laboratories. Dengue virus specific IgM antibodies tend to appear as early as 3 days after infection and remains in circulation for 30 to 60 days. IgG antibodies arise at about 7 days, they reach a peak at 2-3 weeks and persists for life long.[18] NS1 detection has been a promising test to diagnose dengue in its early febrile stage. The NS1 protein was found to be highly conserved in all dengue serotypes, circulating in high levels during the first few days of illness. It correlates with the development of Dengue Fever. There is no cross reaction of the dengue NS1 protein with those of other related *flavi viruses*. [19,20] Out of 120 dengue cases thrombocytopenia ( $<1,00,000/\text{mm}^3$ ) was observed in 45 (37.5%) cases. In 7(5.83%) patients platelet count was  $<20,000/\text{mm}^3$ . One of the WHO diagnostic criteria for DHF is Thrombocytopenia:  $<1$  lakh/ $\text{mm}^3$ . P Jyoti and Basawaraj reported thrombocytopenia in 51.5% patient.[11] Kale A V et al observed thrombocytopenia in 56% patients, platelet count  $<40,000$  in 33.33% cases.[15] Platelet count less than 1,00,000/ml was noticed in 220 cases (68.75%), report published by R D Kulkarni et al.[21]

## Conclusion

The present study reported that dengue infection most commonly seen in males and active adult population. Rapid urbanization in developing countries increases prevalence of dengue. Effective implementation of vector control measures through efforts toward vector breeding source reduction help in reduction of the dengue prevalence in community. This prevention measures will be helpful to us for decreasing other vector borne diseases simultaneously.

## References

1. Guzman MG, Kourig G. Dengue : An update. *Lancet Infect Dis.* 2002 ;2 (1): 33-42.
2. Gupta N, Srivastava S, Jain A, Chaturvedi UC. Dengue in India. *Indian J. Med Res.* 2012;136 (3):373-390.
3. World Health Organization. Dengue: Comprehensive guidelines for prevention and control of dengue and dengue hemorrhagic fever, revised and expanded edition; Chapter 4, clinical manifestations and diagnosis. 2011:24.
4. Smith AW, Chen LH, Massad E, Wilson ME. Threat of dengue to blood safety in dengue – endemic countries. *Emerg Infect Dis.* 2009;15(1):8-11.
5. Peters CJ. Infections caused by arthropod – and Rodent borne viruses. In : Fauci AS, editor. *Harrisons Principles of Internal Medicine* 17th ed. New York: McGraw Hill Medical Publishing Division. 2008:1226- 39.
6. Chakravarti A, Kumaria R, Batra VV, Varma V. Improved detection of dengue virus serotypes from serum samples – Evaluation of single-tube multiplex RT-PCR with cell culture. *Dengue Bulletin.* 2006;30:133-40.
7. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardoso MJ, Devi S. Evaluation of diagnostic test: Dengue. *Nat Rev Microbiol.* 2010;8:S30–7.
8. Datta S, Watal C. Dengue NS1 antigen detection: A useful tool in early diagnosis of dengue virus infection. *Indian J Med Microbiol.* 2010;28(2):107-10.
9. Statler J, Mammen M, Lyons A, Sun W. Sonographic findings of healthy volunteers infected with dengue virus. *J Clin Ultrasound.* 2008;36(7):413-7.
10. Mahesh Kumar, Sharma R, Parihar G, Sharma M. Seroprevalence of Dengue in Central Rajasthan: A Study at a Tertiary Care Hospital. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(9): 933-940.
11. Parameswarappa Jyothi, Basavraj C Metri. Correlation of serological markers and platelet count in the diagnosis of Dengue virus infection. *Adv Biomed Res.* 2015;4:26.
12. Smita Sood A Hospital Based Serosurveillance Study of Dengue Infection in Jaipur (Rajasthan),

- 
- India Journal of Clinical and Diagnostic Research. 2013 Sept.;Vol-7(9): 1917- 1920.
13. Mahesh Kumar, Sharma R, Parihar G, Sharma M. Seroprevalence of Dengue in Central Rajasthan: A Study at a Tertiary Care Hospital. *Int. J. Curr. Microbiol. App. Sci* 2015; 4(9):933-940.
14. Ukey PM, Bondade SA, Paunipagar PV, Powar RM, Akulwar SL. Study of Seroprevalence of Dengue Fever in Central India. *Ind J Community Med.* 2010; 35(4):517-19.
15. Kale AV et.al, clinical profile and outcome of dengue fever from a tertiary care centre at Aurangabad Maharashtra India: an observational study, *IOSR Journal of dental and medical sciences*, 2014;13(9): 14-19
16. S. Ahammad F et al. Clinico- demographic profile of dengue fever in a southindian tertiary care teaching hospital. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2016;5(1):1602-1609.
17. Garg A, Garg J, Rao YK, Upadhyay GC, Sakhuja S. Prevalence of dengue among clinically suspected febrile episodes at a teaching hospital in North India. *J Infect Dis and Immun.* 2011; 3(5):85-89.
18. Vijaykumar TS, Chandy S, Satish N, Abraham M, Abraham P, et al. Is dengue an emerging as a major public health problem? *Ind J Med Res.* 2005;121:100-07.
19. Shrivastava A, Dash PK, Tripathi NK, Sahni AK, Gopalan N, Lakshmana Rao PV. Evaluation of a commercial Dengue NS1 enzyme-linked immunosorbent assay for early diagnosis of dengue infection. *Indian J Med Microbiol*, 2011; 29(1):51-5.
20. Datta S, Wattal C. Dengue NS-1 antigen detection: A useful tool in early diagnosis of dengue virus infection. *Indian J Med Microbio* 2010; 28:107-190.
21. Kulkarni R D, Patil S S, Ajantha G S, Upadhya A K, Kalabhavi A S, Shubhada R M, Shetty P C, Jain P A. Association of platelet count and serological markers of dengue infection- importance of NS1 antigen. *Indian J Med Microbiol*2011;29:359-62.

**Conflict of Interest: Nil**

**Source of support:Nil**